Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2341 to 2355 of 9128 results

  1. Talacotuzumab for untreated acute myeloid leukaemia [ID1262]

    In development Reference number: GID-TA10249 Expected publication date: TBC

  2. Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]

    Awaiting development Reference number: GID-TA10773 Expected publication date: TBC

  3. Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity [TSID11902]

    Awaiting development Reference number: GID-TA11417 Expected publication date: TBC

  4. Camlipixant for treating refractory or unexplained chronic cough [ID6722]

    Awaiting development Reference number: GID-TA11707 Expected publication date: TBC

  5. Itepekimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6547]

    Awaiting development Reference number: GID-TA11716 Expected publication date: TBC

  6. Deutetrabenazine for treating tardive dyskinesia [ID6550]

    In development Reference number: GID-TA11718 Expected publication date: TBC

  7. Third molars (impacted) - prophylactic removal [ID898]

    In development Reference number: GID-TAG525 Expected publication date: TBC

  8. Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]

    In development Reference number: GID-TA11379 Expected publication date: TBC

  9. Pridopidine for treating Huntington's disease [ID6525]

    Awaiting development Reference number: GID-TA11637 Expected publication date: TBC

  10. Semaglutide for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6635]

    Awaiting development Reference number: GID-TA11847 Expected publication date: TBC

  11. Donanemab for reducing the risk of mild cognitive impairment in preclinical Alzheimer's disease [ID6675]

    Awaiting development Reference number: GID-TA11876 Expected publication date: TBC

  12. Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]

    In development Reference number: GID-TA11154 Expected publication date: TBC

  13. Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777]

    Awaiting development Reference number: GID-TA11292 Expected publication date: TBC

  14. Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]

    Awaiting development Reference number: GID-TA11307 Expected publication date:  06 January 2027

  15. Ondansetron for treating alcohol-use disorder [ID6341]

    Awaiting development Reference number: GID-TA11375 Expected publication date: TBC